Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,308 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biological Markers Clear all

Conditions: Lung Cancer
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions: Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab, Surgery; Biological · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • Rochester, New York

Conditions: CRC (Colorectal Cancer)
Interventions: cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer
Interventions: Sunitinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Stroke, Osteopathic Medicine, Physical Examination, Heart Rate Variability (HRV), Energy Expenditure, Patient Reported Outcome (PRO)
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: nintedanib; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Buffalo, New York • Cleveland, Ohio

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: 2-hydroxybenzylamine acetate, Placebo; Drug · Other
Lead sponsor: MTI Biotech Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autism Spectrum Disorder
Interventions: Gabapentin; Drug
Lead sponsor: David Cochran; Other
Eligibility: 13 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Leukemia, Cancer
Interventions: WT 1 Testing; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 2 more

Conditions: Respiratory Tract Infections, Wheezing
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 3 Months to 24 Months
Enrollment: 5 participants
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
Interventions: Adalimumab, Placebo; Biological · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Tuscaloosa, Alabama • Thousand Oaks, California • Jacksonville, Florida + 10 more

Conditions: Cervical Spondylotic Myelopathy
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Preterm Birth
Interventions: Not listed
Lead sponsor: Sera Prognostics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 5,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 18
States / cities: Phoenix, Arizona • Orange, California • San Diego, California + 15 more

Conditions: Crohn's Disease
Interventions: Biopsies, stool and blood collection; Other
Lead sponsor: Enterome; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy, Overweight
Interventions: Low Glycemic Load Diet, High Glycemic Load Diet; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hepatocellular Carcinoma Non-resectable
Interventions: Fluorine-18 fluorocholine; Combination Product
Lead sponsor: Queen's Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Bronchoscopic Biopsy, Blood Sample; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Buffalo, New York

Conditions: Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease
Interventions: Biomarker Assessment; Other
Lead sponsor: CirQuest Labs, LLC; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Jacksonville, Florida • Germantown, Tennessee • Memphis, Tennessee

Conditions: Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions: Lumason, Sonazoid; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Liver Disease
Interventions: 200 µg selenium as selenate, 400 µg selenium as selenate, 200 µg selenium as selenomethionine, Placebo; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Major Depressive Disorder
Interventions: Neuroimaging with Magnetic Resonance Imaging (MRI); Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Single Ventricle Physiology
Interventions: Feeding tolerant, Feeding intolerant, Necrotizing enterocolitis; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Day to 3 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

Study of SU11248 in Men With Advanced Prostate Cancer

Examining Relationships Between Musculoskeletal Function Measurements of Movement Efficiency and Nervous System Function After Chronic Stroke

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients

Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin

WT1 for the Detection of Minimal Residual Disease

Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation

A 24 Month Observational Study of Infants 3-24 Months, Who Suffer an Acute Episode of Respiratory Infection and Wheezing Illness

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

Biomarkers of Cervical Spondylotic Myelopathy

A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor

MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients

Carbohydrates and Related Biomarkers

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer

Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease

Developing Therapies for Traumatic Brain Injury

Y-90 Treatment Response Using Transarterial Radioembolization

Selenium Supplementation of Patients With Cirrhosis

Tracking Brain Biomarkers and Renormalization Associated With Antidepressant Transcranial Magnetic Stimulation Therapy

Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation